Insmed selling Boulder facility to Merck
for $130 million, the company announced Thursday.
The transaction, once it’s completed, will transfer Richmond, Va.-based Insmed’s research and production facility in Boulder to Merck. The Boulder plant’s 80 employees will be offered jobs to continue their work under Merck’s ownership, Insmed said.
Insmed geared its Boulder plant over the past 18 months to produce alternate versions of established biotech drugs.
The first Read the rest of this entry »